Liraglutide (Victoza brand only) joins dulaglutide as a funded GLP-1 receptor agonist for treating type 2 diabetes. This piece of microlearning outlines the differences and similarities between the two medicines.

This piece of microlearning quotes results from the Youth19 Rangatahi Smart Survey, which shows that depression rates among young New Zealanders have risen. 

This piece of microlearning supports the use of topical antiseptics rather than topical antibiotics for common, minor skin infections.

Angiotensin-converting enzyme (ACE) inhibitor availability is changing. This piece of microlearning outlines the changes and gives links to useful resources. 

This piece of microlearning explores the importance of antimicrobial stewardship in Aotearoa New Zealand. 

World Antimicrobial Awareness Week is running from 18-24 November 2022. Aligning with the global action plan endorsed by WHO, the prime minister’s chief science advisor recommends collective and urgent action to mitigate the risk of antimicrobial resistance. Read this aHAH! moment to find out more. 

If you’re after a short piece of education, our bulletins highlight key issues that can promote team discussion and spark ideas for clinical quality improvement initiatives. Read this aHAH! moment to find out more. 

Hospitalisation and death due to asthma are unacceptably high for Māori and Pacific peoples – and little has changed over the past 18 years. The 2020 Asthma and Respiratory Foundation NZ (ARFNZ) asthma guidelines include recommendations to improve care in Māori and Pacific peoples.

EPiC is a free, data-driven tool that enables users to explore individual, practice and national prescribing behaviours. Insights from EPiC data can help users to consider their practice and inform targeted interventions or quality improvement initiatives.

Although triple therapy can reduce the risk of recurrent CVD events by at least 50 per cent over five years, the He Ako Hiringa EPiC dashboard indicates only half of people receive all three types of medicines following a CVD event. Read our latest bulletin for more on triple therapy and team-based initiatives that may help identify and prioritise patients for intensive management.